183 related articles for article (PubMed ID: 12324672)
1. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma.
Currie GP; Fowler SJ; Wilson AM; Sims EJ; Orr LC; Lipworth BJ
Thorax; 2002 Oct; 57(10):865-8. PubMed ID: 12324672
[TBL] [Abstract][Full Text] [Related]
2. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.
Fowler SJ; Orr LC; Wilson AM; Sims EJ; Lipworth BJ
Br J Clin Pharmacol; 2001 Jul; 52(1):93-5. PubMed ID: 11453895
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
4. Fluticasone propionate via the Diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacholine-induced airway hyperresponsiveness.
Langley SJ; Holden J; Derham A; Hedgeland P; Sharma RK; Woodcock A
Chest; 2002 Sep; 122(3):806-11. PubMed ID: 12226017
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma.
Aubier M; Wettenger R; Gans SJ
Respir Med; 2001 Mar; 95(3):212-20. PubMed ID: 11266239
[TBL] [Abstract][Full Text] [Related]
6. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
Fowler SJ; Currie GP; Lipworth BJ
J Allergy Clin Immunol; 2002 Jun; 109(6):929-35. PubMed ID: 12063520
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
Ayres JG; Millar AB; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
[TBL] [Abstract][Full Text] [Related]
8. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma.
Thongngarm T; Silkoff PE; Kossack WS; Nelson HS
J Asthma; 2005 May; 42(4):257-63. PubMed ID: 16032934
[TBL] [Abstract][Full Text] [Related]
9. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients.
Leach CL; Kuehl PJ; Chand R; Ketai L; Norenberg JP; McDonald JD
Ann Allergy Asthma Immunol; 2012 Mar; 108(3):195-200. PubMed ID: 22374204
[TBL] [Abstract][Full Text] [Related]
10. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone.
Colice G; Martin RJ; Israel E; Roche N; Barnes N; Burden A; Polos P; Dorinsky P; Hillyer EV; Lee AJ; Chisholm A; von Ziegenweidt J; Barion F; Price D
J Allergy Clin Immunol; 2013 Jul; 132(1):45-54. PubMed ID: 23591272
[TBL] [Abstract][Full Text] [Related]
11. Effects on small airway obstruction of long-term treatments with beclomethasone/formoterol hydrofluoroalkane (metered-dose inhaler) versus fluticasone/salmeterol (dry-powder inhaler) in asthma: a preliminary study.
Corda L; Gardenghi GG; Modina D; Montemurro LT; Novali M; Tantucci C
Allergy Asthma Proc; 2011; 32(6):29-34. PubMed ID: 22221427
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.
Tonnel AB; Bons J; Legendre M; Prud'Homme A; Bugnas B; Evano-Celli I; Stuart AM
Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683
[TBL] [Abstract][Full Text] [Related]
13. Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma.
Lee DK; Haggart K; Currie GP; Bates CE; Lipworth BJ
Br J Clin Pharmacol; 2004 Jul; 58(1):26-33. PubMed ID: 15206989
[TBL] [Abstract][Full Text] [Related]
14. Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function.
Lee DK; Bates CE; Currie GP; Cowan LM; McFarlane LC; Lipworth BJ
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):253-8. PubMed ID: 15478385
[TBL] [Abstract][Full Text] [Related]
15. A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness.
Fardon TC; Burns P; Barnes ML; Lipworth BJ
Ann Allergy Asthma Immunol; 2006 Mar; 96(3):422-30. PubMed ID: 16597076
[TBL] [Abstract][Full Text] [Related]
16. Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma.
Currie GP; Stenback S; Lipworth BJ
Br J Clin Pharmacol; 2003 Jul; 56(1):11-7. PubMed ID: 12848770
[TBL] [Abstract][Full Text] [Related]
17. Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.
Lumry WR; Conway MM; LaForce CF; Pearlman DS; Scott CA; Herje NE; Wu WW; Crim C
Ann Allergy Asthma Immunol; 2006 Jan; 96(1):51-9. PubMed ID: 16440533
[TBL] [Abstract][Full Text] [Related]
18. Short-term lower leg growth in 5- to 11-year-old asthmatic children using beclomethasone dipropionate inhalers with chlorofluorocarbon or hydrofluoroalkane propellants: a 9-week, open-label, randomized, crossover, noninferiority study.
Wolthers OD; Walters EG
Clin Ther; 2011 Aug; 33(8):1069-76. PubMed ID: 21784529
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group.
Perruchoud AP; Lundback B; Yigla M; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S35-41. PubMed ID: 10919684
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate.
Fowler SJ; Orr LC; Sims EJ; Wilson AM; Currie GP; McFarlane L; Lipworth BJ
Chest; 2002 Aug; 122(2):618-23. PubMed ID: 12171841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
